Merck acquires start-up biotech for $1.1 billion

Share this article:
Merck entered a deal to acquire biotech firm Sirna Therapeutics for $1.1 billion. The deal will give Merck access to a new class of medicines based on RNA interference (RNAi) technology. RNAi is a considered a powerful mechanism for inactivating particular genes and is used widely in laboratories to study genetic functions. Both Merck and Sirna are hoping the technique can be harnessed to kill viruses or tumors for instance by “turning off” their genes. “We believe that RNAi could significantly change the way in which we go about discovering and developing drugs, and could become a new way to treat patients with unmet medical needs,” said Merck research president Peter Kim in a statement.
Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.